関連する実験動画

Updated: Feb 22, 2026

In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion

In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion

Published on: November 10, 2011

肝臓内細胞経路のプライミングにより,ナノ粒子の肝胆清浄が加速されます

Yunfeng Ren¹, Fang Mei¹, Huixu Lu¹

¹School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, P.R. China.

|February 21, 2026

まとめ

クラトリン媒介性エンドサイトーシス (CME) を抑制するために肝臓をプリミングすると,ナノ粒子の除去が加速されます. この戦略は,肝細胞からのエクソサイトーシスを強化し,ナノ粒子の蓄積を軽減し,ナノ医薬品の投与を改善します.

科学分野:

ナノテクノロジーナノテクノロジー
肝胆科学ヘパト・ビリアー科学
薬物の配達薬物の配達

背景:

ナノ医薬品の長期間の肝臓蓄積は,特に生物分解不可能なナノ粒子の臨床使用を妨げます.
現在の戦略は,肝臓の摂取量を減らすことに重点を置くが,摂取後の加速排泄に対処する戦略はほとんどない.

研究の目的:

ナノ粒子の肝胆排泄を加速するための広く適用可能な戦略を開発する.
ナノ粒子のクリアランスにおける肝臓内細胞経路の役割を調査する.

主な方法:

マウスにおけるクロプロマジンによるクラスリン媒介性内分細胞症 (CME) の抑制.
ヘパトサイトとマクロファージからのナノ粒子の細胞内密輸とエクソサイトーシスの評価.
様々なナノ粒子の肝胆清除と肝臓保持の評価.
ネズミの腫瘍モデルでの試験で,ナノ医薬品の投与効率を評価する.

主要な成果:

CME阻害は,肝細胞とマクロファージからのナノ粒子エクソサイトーシスを著しく強化しました.
変化した細胞内輸送は,より速いエクソサイトーシスのために,ナノ粒子をゴルギに誘導した.
クロロプロマジンプライミングは,肝胆清除を加速し,様々なナノ粒子の肝臓保持を減少させた.
肝臓CME阻害は,腫瘍標的の有効性を損なうことなく,除去を加速しました.

結論:

CME阻害による肝臓内細胞経路のプリミングは,ナノ粒子の除去を加速するための汎用的な戦略です.
このアプローチは,ナノ医薬品の肝臓の蓄積を減らすための既存の方法の補完的な戦略を提供します.

キーワード:

腸内細胞経路は内細胞経路である.エクソサイトーシスエクソサイトーシスヘパトビリヤーのクリアランスは細胞内での人身売買ナノ粒子 (nanoparticle) とは,ナノ粒子を構成するものです.サイズ依存型である.

さらに関連する動画

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

Published on: October 13, 2018

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications

Published on: April 28, 2015

関連する概念動画

Hepatic Drug Clearance: Role of Transporters

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...

Drug Elimination: Non-Renal Routes

Drug Elimination: Non-Renal Routes

The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...

Hepatic Drug Excretion: Enterohepatic Cycling

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Bioavailability Enhancement: Drug Permeability Enhancement

Bioavailability Enhancement: Drug Permeability Enhancement

Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...